Northcoast Research Upgrades Zimmer Holdings to Buy (ZMH)
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Zimmer Holdings in a research note to investors on Tuesday, May 1st. They now have a $66.00 price target on the stock. Separately, analysts at Mizuho raised their price target on shares of Zimmer Holdings from $66.00 to $68.00 in a research note to investors on Friday, April 27th. They now have a “buy” rating on the stock. Finally, analysts at BMO Capital Markets upgraded shares of Zimmer Holdings from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, April 27th.
Zimmer Holdings traded up 0.34% on Thursday, hitting $62.11. Zimmer Holdings has a 52-week low of $47.00 and a 52-week high of $68.64. The company has a market cap of $10.940 billion and a price-to-earnings ratio of 15.06.
Zimmer Holdings last posted its quarterly earnings results on Thursday, April 26th. The company reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. Analysts expect that Zimmer Holdings will post $1.16 EPS next quarter.
Zimmer Holdings, Inc. (Zimmer) designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants and related surgical products.